{"podcast":{"title":"The Fellow on Call: The Heme/Onc Podcast","slug":"the-fellow-on-call-the-heme-onc-podcast-4669989","podcast_index_feed_id":4669989,"rss_url":"https://www.thefellowoncall.com/tfocpodcast?format=rss","website_url":"https://www.thefellowoncall.com/tfocpodcast/","image_url":"https://images.squarespace-cdn.com/content/v1/61b273ac9be6aa2250498c9e/1641065434990-8BV6L7UFJF4JCCKCY6S1/Untitled+design+%281%29+copy.png?format=1500w","author":"Ronak Mistry","episode_count":164,"summary":"We quickly realized we knew very little about hematology and oncology when we started fellowship. Our goal is to bring you the fundamentals, core concepts and important management approaches in our field, driven by the latest evidence and expert opinion. In each episode, we will provide bite-sized, simplified approaches to common questions in a way that is perfect for anyone interested in hematology and oncology, from students and trainees to advanced practice providers and practicing physicians.","last_synced_at":"2026-06-24T18:17:58.817010+00:00","page_url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989"},"episode":{"title":"Episode 149: Myeloma Series, Pt. 9 - Maintenance for Multiple Myeloma (2026)","slug":"episode-149-myeloma-series-pt-9-maintenance-for-multiple-myeloma-2026","published_at":"2026-03-18T08:00:50+00:00","page_url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-149-myeloma-series-pt-9-maintenance-for-multiple-myeloma-2026","show_page_url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989","url":"https://www.thefellowoncall.com/tfocpodcast/myelomamaint","audio_url":"https://static1.squarespace.com/static/61b273ac9be6aa2250498c9e/t/69b95d2803a71d6ec17d2329/1774970554871/The+Fellow+On+Call+-+Multiple+Myeloma+Maintenance+Therapy+-+Mix.mp3","summary":"This week, we turn our attention to what we do in the maintenance setting for management of myeloma. At this point, our patient has gone through initial therapy; for patients who are able to undergo a transplant, we have consolidated their disease with a transplant; and now, we want to maintain that response using a lower dose of therapy, all while trying to minimize toxicity and maximize the patient’s quality of life. We discuss this in detail in this week’s episode! Content: - Why is lenolidomide (revlimid) our current standard of care? - What data do we have to add anti CD38 antibodies? - How is MRD being considered in this space? ** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube","meta_description":"This week, we turn our attention to what we do in the maintenance setting for management of myeloma. At this point, our patient has gone through initial t…","key_points":[],"chapters":[],"topics":[],"duration_seconds":null,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-fellow-on-call-the-heme-onc-podcast-4669989/episodes/episode-149-myeloma-series-pt-9-maintenance-for-multiple-myeloma-2026/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-149-myeloma-series-pt-9-maintenance-for-multiple-myeloma-2026.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}